Drugs / idraparinux
last change Jan 2010 re-read 2 minutes ago

idraparinux

targets F10 via inhibition

Developed for
pulmonary embolism · venous thromboembolism · atrial fibrillation
Investigated by
Sanofi

Trials 4 · a red edge is where a trial was stopped

2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00071279 Nov 2003 → Dec 2005 pulmonary embolism, venous thromboembolism Sanofi Completed No outcome recorded
Phase 3 NCT00070655 Sep 2003 → Mar 2006 atrial fibrillation Sanofi Completed No outcome recorded
Phase 3 NCT00062803 Jun 2003 → Oct 2005 pulmonary embolism Sanofi Completed No outcome recorded
Phase 3 NCT00067093 May 2003 → Sep 2005 venous thromboembolism Sanofi Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00311090 Comparator Apr 2006 → Jan 2008 venous thromboembolism Sanofi Completed No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 8 sources stand behind the page.

FieldValueCited text
Known as idraparinux ClinicalTrials.gov intervention name — accepted as the source's own label NCT00071279
2

NCT00070655

NCT00311090

Known as Idraparinux de sodio ChEMBL registry synonym — accepted as the source's own label CHEMBL5314801
Known as Idraparinux nonasodium salt ChEMBL registry synonym — accepted as the source's own label CHEMBL5314801
Known as Idraparinux sodique ChEMBL registry synonym — accepted as the source's own label CHEMBL5314801
Known as idraparinux sodium “SR34006 (idraparinux sodium) Injection” NCT00070655
1

“SR34006 (idraparinux sodium) Injection” NCT00071279

Known as ORG-34006 ChEMBL registry synonym — accepted as the source's own label CHEMBL5314801
Known as SanOrg34006 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00067093
Known as SR34006 SR34006 (idraparinux sodium) Injection” NCT00070655
2

SR34006 (idraparinux sodium) Injection” NCT00071279

NCT00062803

Action Inhibit “Idraparinux is an inhibitor of activated factor X (FXa) with a long half-life allowing once-weekly dosing.” PMID 20088937 Jan 2010
1

“Coagulation factor X inhibitor” CHEMBL5314801

Route Subcutaneous subcutaneous idraparinux (2.5 mg weekly)” PMID 18294998 Jan 2008
Target F10 “Coagulation factor X inhibitor” CHEMBL5314801